# Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

> **NCT02952729** · PHASE1 · COMPLETED · sponsor: **Mersana Therapeutics** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Advanced Nonsmall Cell Lung Cancer
- Advanced Gastric Cancer

## Interventions

- **DRUG:** XMT-1522

## Key facts

- **NCT ID:** NCT02952729
- **Lead sponsor:** Mersana Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-21
- **Primary completion:** 2019-01-28
- **Final completion:** 2019-01-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952729, "Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02952729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*